HEALTH PREFERENCES AFTER CABG OR PCI FOLLOWING AN ACUTE MYOCARDIAL INFARCTION
CARDIOVASCULAR RISK OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS COMPARED TO OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS
THE USE OF A PROBABILISTIC DECISION MODEL TO ASSESS THE COST-EFFECTIVENESS OF DRUG-ELUTING STENTS IN ALTERNATIVE PATIENT SUB-GROUPS
LOWER CARDIOVASCULAR RISK ASSOCIATED WITH PIOGLITAZONE MONOTHERAPY COMPARED TO INSULIN MONOTHERAPY
THE STATE OF THE SCIENCE OF HRQOL ASSESSMENT IN CANCER
7215 COST-EFFECTIVENESS OF DIAGNOSTIC, STAGING, AND TREATMENT OPTIONS FOR MELANOMA
COST-EFFECTIVENESS OF ANASTROZOLE VS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (EBC)
COST-EFFECTIVENESS (CE) ANALYSIS OF INTERFERON-ALPHA IN HIGH-RISK MELANOMA PATIENTS
THE EFFECT OF PRESCRIPTION DRUG COVERAGE ON THE COST OF CARE FOR MEDICARE BENEFICIARIES WITH ASTHMA
THE EXCESS COST OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE FROM A MANAGED-CARE PERSPECTIVE
COST-EFFECTIVENESS OF INFLUENZA VACCINE IN 6–24 MONTH OLD CHILDREN
AN ECONOMIC ANALYSIS OF RAPID TESTS AND ANTIVIRAL TREATMENTS FOR INFLUENZA IN CHILDREN
ASSESSING THE COST-EFFECTIVENESS OF COX-2 SPECIFIC INHIBITORS FOR ARTHRITIS IN THE VETERANS HEALTH ADMINISTRATION
A COST-EFFECTIVENESS ANALYSIS OF BIOLOGICAL TREATMENTS FOR RHEUMATOID ARTHRITIS
REVALUATION OF THE ORIGINAL CEDARS-SINAI RHEUMATOID ARTHRITIS HEALTH-RELATED QUALITY OF LIFE (CSHQ-RA) INSTRUMENT
THE DEVELOPMENT OF PROPENSITY SCORES FROM ADMINISTRATIVE DATABASES FOR THE ANALYSIS OF THE EFFECTIVENESS OF AN OSTEOARTHRITIS ACADEMIC DETAILING SERVICE ON PRESCRIBING BEHAVIOUR
DO DRUG PRICES REFLECT VALUE? DO FORMULARY POLICIES?
DECISION-MAKER'S PERCEPTIONS OF ACCESS TO HIGH COST DRUGS (HCDS) IN PUBLIC HOSPITALS IN AUSTRALIA
COMPARISON OF REIMBURSEMENT SYSTEMS OF VARIOUS COUNTRIES IN CENTRAL AND EASTERN EUROPE, AFRICA, AND MIDDLE EAST
IMPACT OF MEMBER COST-SHARING LEVELS ON POPULATION-BASED STATIN USE RATES
A FRAMEWORK FOR COSTING RECOMMENDATIONS IN PHARMACOECONOMIC GUIDELINES
CE2 PANEL ANALYSIS OF CENSORED MEDICAL COST DATA
THE COSTS OF ADJUVANT CHEMOTHERAPY IN EARLY STAGE BREAST CANCER PATIENTS
AN ACTUARIAL APPROACH TO ESTIMATING THE STREAM OF COSTS ASSOCIATED WITH BREAST AND COLORECTAL CANCER
HEALTH CARE MODELING
MODELS IDENTIFYING VARIABLES INFLUENCING PHYSICIAN ADOPTION OF NEWLY LAUNCHED PHARMACEUTICALS IN THE UNITED STATES
PREDICTING PHARMACY COSTS USING HEALTH-RELATED QUALITY-OF-LIFE AND PHARMACY CLAIMS MEASURES IN ADULT ASTHMATICS
HOW ROBUST IS COST-EFFECTIVENESS RATIO TO MISSING DATA IMPUTATION? ANALYSIS OF LONG-TERM CLINICAL TRIAL IN PARKINSONS DISEASE
PATIENT PREFERENCES FOR COLORECTAL CANCER (CRC) SCREENING STRATEGIES
COST EFFECTIVENESS OF SCREENING AND STATIN THERAPY IN CLINICAL GUIDELINES FOR CARDIOVASCULAR PROPHYLAXIS
FACTORS IMPACTING MAMMOGRAPHY SCREENING IN RURAL AND URBAN AREAS
ECONOMIC EVALUATION OF SCREENING FORTHEA-ADDUCIN GENE VARIANT IN HYPERTENSIVE PATIENTS
CLAIM-BASED DRUG WASTAGE ESTIMATION
PREVALENCE AND CORRELATES OF POTENTIALLY INAPPROPRIATE PRESCRIBING AMONG THE AMBULATORY ELDERLY IN 2001
EVALUATING CLINICAL AND FINANCIAL OUTCOMES ASSOCIATED WITH A RETROSPECTIVE DRUG UTILIZATION REVIEW PROGRAM
A DYNAMIC MODEL OF BUDGET IMPACT ANALYSES
CAPTURING PATIENT-REPORTED COMPLIANCE DATA IN A NINE-COUNTRY PRODUCT REGISTRY USING MEMS CAP DEVICES
COMPARING PATIENT-REPORTED MEDICATION COMPLIANCE WITH ELECTRONICALLY MONITORED MEDICATION COMPLIANCE IN A 12-MONTH INTERNATIONAL REGISTRY
COMPARISION OF ADHERENCE TO ANTIHYPERTENSIVES IN A MANAGED CARE POPULATION
CLINICAL AND ECONOMIC OUTCOMES OF NON-ADHERENCE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN PATIENTS WITH HIV
ASSESSING EFFECTIVENESS IN THE PRESENCE OF TREATMENT SWITCHING
THE EFFECTS OF ANTIDEPRESSANT DRUGS ON THE RISK OF COLORECTAL CANCER
COMORBIDITY INFLUENCE INDEX
AN AUTOMATED METHOD TO INFER MORBIDITY DESCRIPTIONS FROM PATIENT PHARMACY PROFILES
IS THE CURRENT METHOD OF VALUING HEALTH OUTCOMES IN COST-EFFECTIVENESS ANALYSIS VALID?
COMPARISON OF DISCRETE CHOICE EXPERIMENT (DCE) WITH VISUAL ANALOG SCALING (VAS) METHODS FOR ESTIMATING PREFERENCES FOR PHYSICAL DISABILITY STATES
UNDERSTANDING THE CHARACTERISTICS OF NON TRADERS IN TTO UTILITY ELICITATION
DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED USEFULNESS SCALE TO EVALUATE ANTIEPILEPTIC PHARMACOTHERAPY IN PATIENTS WITH EPILEPSY
THE IMPACT OF USING EITHER THE FRAMINGHAM OR THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY RISK FORMULAE IN DIABETES HEALTH ECONOMICS MODELING
INDIVIDUALIZED PREDICTIVE DISEASE MODELING AS A TOOL TO IMPROVE EFFICACY AND EFFICIENCY OF DISEASE MANAGEMENT PROGRAMS FOR DIABETES MELLITUS
OUTCOMES ASSOCIATED WITH THE INTRODUCTION OF THIAZOLIDINEDIONE THERAPY IN ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLITUS
DRIVERS OF TREATMENT PREFERENCE AMONG INDIVIDUALS WITH TYPE-2 DIABETES
AN ECONOMIC ANALYSIS OF ANTIPSYCHOTIC TREATMENT FOR SCHIZOPHRENIA
IMPACT OF OPEN ACCESS TO ATYPICAL ANTIPSYCHOTICS IN CALIFORNIA MEDICAID
COST-EFFECTIVENESS OF METHYLPHENIDATE OROS FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
ASSESSMENT OF HEALTH STATE UTILITIES FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN CHILDREN USING PARENT-BASED STANDARD GAMBLE SCORES
ESTIMATING COST-EFFECTIVENESS OF DRUGS THAT DELAY DISABILITY PROGRESSION IN MULTIPLE SCLEROSIS USING NET BENEFIT REGRESSION MODEL METHODS
COST-EFFECTIVENESS OF MIGRAINE PREVENTION
MEDICAL SERVICES UTILIZATION FOR PATIENTS WITH PARKINSON'S DISEASE IN A STATE MEDICAID PROGRAM
BURDEN OF ILLNESS IN ALZHEIMER'S DISEASE IN THE UNITED KINGDOM
EVALUATION OF GENERIC DISPENSING INCENTIVE PROGRAM (GDIP)
SESSION IV
EFFECT OF COPAY INCREASE ON FOUR MEASURES OF COMPLIANCE
CHALLENGES FOR EXAMINING THE ECONOMICS OF PHARMACOGENOMICS
RHEUMATOID ARTHRITIS IMPACT OF DISEASE AND DRUG THERAPY
INFLIXIMAB DOSING PATTERNS IN RHEUMATOLOGY PRACTICES
ECONOMIC EVALUATION OF SELF-INJECTION VS AMBULATORY CARE OF ANTI-RHEUMATOID BIOLOGICS (ETANERCEPT) IN JAPAN
COST-EFFECTIVENESS OF TUMOR NECROSIS FACTOR ALPHA lpar;TNF-ALPHA) INHIBITORS AS FIRST-LINE AGENTS IN RHEUMATOID ARTHRITIS
COST-EFFECTIVENESS OF ADALIMUMAB (HUMIRA™) IN THE TREATMENT OF US PATIENTS WITH RHEUMATOID ARTHRITIS (RA)
COST-EFFECTIVENESS OF TREATMENT STRATEGIES FOR RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE
ASSESSMENT OF PATIENT-REPORTED OUTCOMES AMONG OSTEOARTHRITIC PATIENTS
THE RELATIONSHIP BETWEEN GASTROINTESTINAL SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE IN KOREAN PATIENTS WITH RHEUMATIC DISEASES
HEALTH RELATED QUALITY OF LIFE OF CHRONIC LOW BACK PAIN AND OSTEOARTHRITIS PATIENTS RECEIVING FENTANYLTRANSDERMAL SYSTEM
IMPROVING THE SENSITIVITY OF PHYSICAL FUNCTION MEASURES IN RHEUMATOID ARTHRITIS
REVALUATION OF THE CEDARS-SINAI RHEUMATOID ARTHRITIS HEALTH-RELATED QUALITY OF LIFE (CSHQ-RA) SHORT FORM INSTRUMENT
PATIENT PREFERENCE AND WILLINGNESS-TO-PAY FOR VIOXX® AS A TREATMENT FOR OSTEOARTHRITIS RELATIVE TO NSAIDS
BURDEN OF OSTEOARTHRITIS AND ITS TREATMENT ON PATIENTS
CONTRIBUTION OF PAIN, SITE OF PAIN AND NUMBER OF JOINTS AFFECTED ON PRODUCTIVITY LOSS AMONG WORKERS AND NON-WORKERS WITH OSTEOARTHRITIS
ETHNIC VARIATIONS IN PREFERENCE FOR TOTAL KNEE REPLACEMENT IN PATIENTS WITH OSTEOARTHRITIS
TRENDS IN THE USE OF PATIENT REPORTED OUTCOMES IN OSTEOARTHRITIS CLINICAL TRIALS AND SUBSEQUENT PRODUCT LABELS
CHARACTERIZATION OF THE TREATMENT OF RHEUMATOID ARTHRITIS FOR PATIENTS PRESCRIBED TUMOR NECROSIS FACTOR-ALPHA INHIBITORS
RACIAL DISPARITIES IN PRESCRIBING OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS OVER OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS IN A MEDICAID MANAGED CARE POPULATION
EPOETIN ALFA AND DARBEPOETIN ALFA ANEMIA TREATMENT OUTCOMES IN CANCER PATIENTS FROM A VA PERSPECTIVE
IMPACT OF CHEMOTHERAPY-INDUCED DIARRHEA ON MANAGEMENT PATTERNS AND RESOURCE UTILIZATION AMONG CANCER PATIENTS
POTENTIAL IMPACT OF WANING OF VACCINE-INDUCED IMMUNITY AGAINST HUMAN PAPILLOMAVIRUS 16/18
TECHNOLOGY ADVANCES AND TREATMENT PATTERN VARIATIONS IN ONCOLOGY
ANALYSIS OF OVER 2400 MODERN PHASE I CANCER TRIALS
FACTORS INFLUENCING PHYSICIAN RECOMMENDATION FOR IMATINIB MESYLATE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
TRENDS IN CHEMOTHERAPY USE, OUTCOMES, AND COST FOR PATIENTS WITH ADVANCED NONSMALL LUNG CANCER
OUTCOMES AND COSTS OF SURROGATE END-POINTS (SES) AND BIOMARKERS IN PHASE I ONCOLOGY CLINICAL TRIALS
COST EFFECTIVENESS OF ADDING BISPHOSPHONATESTO THE NON-SURGICAL ANDROGEN DEPRIVATION THERAPY FOR FRACTURE REDUCTION IN PATIENTS WITH NON-METASTATIC PROSTATE CANCER
THE COST-EFFECTIVENESS OF METHYL AMINOLEVULINATE PHOTODYNAMICTHERAPY (MAL-PDT) FOR BASAL CELL CARCINOMA
COST-EFFECTIVENESS ANALYSIS OF DOSE-DENSE CHEMOTHERAPY WITH FILGRASTIM AS POSTOPERATIVE ADJUVANT TREATMENT OF BREAST CANCER
ECONOMIC BURDEN OF PANCREATIC CANCER AND TREATMENT FAILURE
AN ECONOMIC ANALYSIS OF RADIATION VERSUS RADIATION PLUS GOSERELIN IN THE TREATMENT OF LOCALLY ADVANCED PROSTATE CANCER
AN ECONOMIC EVALUATION OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER FROM A US HEALTH CARE PERSPECTIVE
DIRECT MEDICAL COSTS OF MANAGING TOXICITIES RELATED TO TAXANE THERAPY FOR METASTATIC BREAST CANCER IN THE UNITED STATES
ECONOMIC BURDEN OF PROSTATE CANCER AMONG HOSPITALIZED PATIENTS
THE HEALTH CARE COST OF SMOKING IN CANADA
COST ANALYSIS OF LUNG CANCER TREATMENT IN TAIWAN
THE COST-EFFECTIVENESS ANALYSIS RECOMBINANT HUMAN ERYTHROPOIETIN GROWTH FACTORS VS. TRANSFUSION IN CHEMOTHERAPY CANCER PATIENTS
PRELIMINARY ECONOMIC ANALYSIS OF THE AMERICAN CANCER SOCIETY GUIDELINES FOR MAMMOGRAPHY SCREENING IN AVERAGE-RISK WOMEN UNDER 70 YEARS OF AGE
SHORT-TERM PSYCHOSOCIAL COUNSELING FOR PATIENTS WITH NEWLY-DIAGNOSED PROSTATE CANCER
THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE CORE QUESTIONNAIRE (EORTC QLQ-C30)
XEROSTOMIA SYMPTOMS
QUALITY OF LIFE OF NEWLY DIAGNOSED PROSTATE CANCER PATIENTS IN A PUBLIC VS. PRIVATE SETTING
CASE-MATCHED CONTROLLED STUDY SHOWS MEN PREFER PROSTATE BRACHYTHERAPYTO CONFORMAL RADIATION THERAPY
ARE HEALTH STATES “TIMELESS”? A TEST OFTHE UTILITY INDEPENDENCE ASSUMPTION USING A REPEATED MEASURES DESIGN
THE BREAST CANCER SCREENING RATES OF GEORGIA MEDICAID RECIPIENTS
GAPS IN COLORECTAL CANCER OUTCOMES RESEARCH
MEASURING CHEMOTHERAPY EFFECTIVENESS IN NATURALISTIC SETTINGS
USING THE DIFFERENCE IN DIFFERENCE METHOD TO UNDERSTAND OUTCOMES IN PROSTATE CANCER
WEIGHT OR NOT TO WEIGHT?
CENSORED MEDICAL COST ESTIMATION
SMOKING BEHAVIOR AMONG COPD PATIENTS, SASKATCHEWAN CANADA
IMPACT OF ANEMIA ON HOSPITALIZATION AND MORTALITY IN ELDERLY PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND CHRONIC KIDNEY DISEASE
ESTIMATING COST-EFFECTIVENESS OF INHALED CORTICOSTEROIDS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE PRESENCE OF MISSING DATA
EPISODES OF RESPIRATORY CARE FOR MANAGED CARE PATIENTS WITH COPD
ECONOMIC BURDEN OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN A STATE HEALTH INSURANCE PROGRAM
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC RESPIRATORY DISEASE
PATIENTS' PERSISTENCE AND ADHERENCE WITH GLAUCOMATHERAPY
MEDICATION ADHERENCE RATES AND DISEASE SEVERITY CHANGES IN PSORIASIS
PRIOR AUTHORIZATION OF TOPICAL RETINOIDS NEEDED? EVIDENCE FROM OUTPATIENT US NATIONAL PRACTICE DATA
COST-UTILITY OF COCHLEAR IMPLANTS A SOCIETAL PERSPECTIVE ANALYSIS
THE COST-EFFECTIVENESS OF OTOTOPICAL CIPROFLOXACIN AND DEXAMETHASONE VERSUS OTOTOPICAL OFLOXACIN FOR THE TREATMENT OF OTORRHEA IN PATIENTS WITH TYMPANOSTOMY TUBES
PATIENT-REPORTED IMPACT OF AGE-RELATED MACULAR DEGENERATION
A COST-EFFECTIVENESS ANALYSIS OF TREATING OPEN ANGLE GLAUCOMA
ECONOMIC RESOURCES UTILIZED IN A COHORT OF PATIENTS WITH AGE-RELATED MACULAR DEGENERATION (AMD)
ELIGIBILITY, UTILIZATION, AND COSTS IN A CALIFORNIA MEDICAID LUPUS POPULATION
THE COST-EFFECTIVENESS OF METHYL AMINOLEVULINATE PHOTODYNAMIC THERAPY (MAL-PDT) FOR DIFFICULT TO TREAT ACTINIC KERATOSES
A COST COMPARISON OF TOPICAL 5% FLUOROURACIL VS. CRYOSURGERY FOR THE TREATMENT OF ACTINIC KERATOSIS
ESTIMATE OF DIRECT MEDICAL COSTS ASSOCIATED WITH THE USE OF CONVENTIONAL SYSTEMIC AGENTS IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS
FACTORS AFFECTING HEALTH CARE EXPENDITURES AMONG PATIENTS WITH DERMATOPHYTOSIS
MEDICATION AND HEALTH CARE SERVICE UTILIZATION RELATED TO DEPRESSIVE SYMPTOMS IN OLDER ADULTS WITH PSORIASIS
A COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION (AMD) WITH MONOCULAR VERSUS BILATERAL DISEASE
VALIDATION OF A NEW SELF-ASSESSMENT QUESTIONNAIRE AND THE SKINDEX-29 QUALITY OF LIFE (QOL) INSTRUMENT FOR CHRONIC HAND DERMATITIS (CHHD)
IMPROVED HEALTH-RELATED QUALITY OF LIFE FOLLOWING SUSTAINED REDUCTIONS IN ANTI DS-DNA ANTIBODYS [ADSDNA AB] IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AFTER TREATMENT WITH LJP394
THE IMPACT OF THE SYSTEM TO MANAGE ACCUTANE-RELATED TERATOGENICITY(TM) (SMART™) RISK MANAGEMENT PROGRAM ON ISOTRETINOIN PRESCRIBING TRENDS
EFFECT OF ZIPRASIDONE INITIAL DOSING ON DISCONTINUATION IN SCHIZOPHRENIA
GAPS IN ANTIPSYCHOTIC MEDICATION AND RISK OF HOSPITALIZATION FOR THE TREATMENT OF SCHIZOPHRENIA IN MANAGED CARE SETTINGS
FATORS ASSOCIATED WITH SECOND-GENERATION ANTIPSYCHOITC USE IN THE CALIFORNIA MEDICAID (MEDI-CAL) PATIENTS WITH SCHIZOPHRENIA
ATYPICAL ANTIPSYCHOTIC TREATMENT ADHERENCE AND PERSISTENCE IN A STATE MEDICAID PROGRAM
WITHDRAWN
ANTIPSYCHOTIC TREATMENT AND DIABETES IN A PRIVATELY INSURED POPULATION
TREATMENT AND ECONOMIC OUTCOMES IN PEDIATRIC INPATIENTS TREATED WITH ATYPICAL ANTIPSYCHOTICS
SWITCHING & DISCONTINUATION OF SERTRALINE, PAROXETINE AND CITALOPRAM THERAPY
ANALYSIS OF ANTIDEPRESSANT MEDICATION UTILIZATION AND ADHERENCE OF MANAGED CARE PATIENTS ENROLLED IN A MEDICATION ADHERENCE PROGRAM
PEDIATRIC ANTIDEPRESSANT PRESCRIPTION PATTERNS
ANTIDEPRESSANT USE AND RISK OF SUICIDE ATTEMPT IN ADOLESCENTS WITH MAJOR DEPRESSIVE DISORDER
THE IMPACT OF PREMATURE DISCONTINUATION OF ANTIDEPRESSANTTHERAPY IN MAJOR DEPRESSIVE DISORDER
USING PATIENT REPORTED OUTCOMES (PROS) TO DETERMINE DEPRESSION AND ANXIETY POPULATIONS IN FOUR COUNTRIES
CANADIAN NETWORK FOR BIPOLAR DISORDER (CAN-BD)
FACTORS ASSOCIATED WITH SECOND-GENERATION ANITPSYCHOTICS IN THE CALIFORNIA MEDICAID (MEDI-CAL) PATIENTS WITH BIPOLAR DISORDERS
OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER
ANTIDEPRESSANT MONOTHERAPY AND OUTCOMES FOR PATIENTS WITH BIPOLAR DISORDER
THE EFFECTS OF OPEN ACCESS ON DRUG THERAPY OUTCOMES FOR PATIENTS WITH BIPOLAR DISORDER IN THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM
ESCITALOPRAM IN THE TREATMENT OF KLEPTOMANIA
RISK OF REHOSPITALIZATION
RELATIONSHIP BETWEEN QUETIAPINE DOSE AND LEVELS OF MENTAL HEALTH RESOURCE USE AMONG PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER
CONVENTIONAL ANTIPSYCHOTICS CAN BE COST EFFECTIVE FOR BROADLY DEFINED TREATMENT RESISTANT OR INTOLERANT SCHIZOPHRENIA
COST-EFFECTIVENESS EVALUATION OF LONG-ACTING RISPERIDONE INJECTION
UTILIZATION ANALYSIS OF HEALTH CARE RESOURCES FOR PATIENTS TREATED WITH ATYPICAL ANTIPSYCHOTICS
A COMPARISON OF THE COST-EFFECTIVENESS OF OLANZAPINE FOR THE TREATMENT OF SCHIZOPHRENIA IN SELECTED NON-OECD COUNTRIES
OUT-OF-POCKET DRUG EXPENDITURES AND PATTERNS OF DEPRESSION IN THE ELDERLY
DIRECT HEALTH CARE COST OF DEPRESSIVE DISORDERSIN THE UNITED STATES
COST-EFFECTIVENESS OF INTERVENTIONS TO IMPROVE PATIENT MEDICATON COMPLIANCE IN MAJOR DEPRESSIVE DISORDER
COST-EFFECTIVENESS OF ESCITALOPRAM VERSUS CITALOPRAM IN THE TREATMENT OF SEVERE DEPRESSION IN AUSTRIA
WITHDRAWN
COST AND COMORBIDITIES ASSOCIATED WITH BIPOLAR DISORDER
COMPARISON OF BIPOLAR DISORDER-RELATED COSTS AMONG PATIENTS WITH AND WITHOUT COMORBID DIABETES
DRUG TREATMENT PATTERNS OF BIPOLAR DISORDER AND ASSOCIATED COSTS
COST-EFFECTIVENESS OF OLANZAPINE VERSUS LITHIUM FOR THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER IN AUSTRALIA
SERVICE UTILIZATION AND COSTS FOR BIPOLAR DEPRESSION
THE COSTS OF POLY-PHARMACY, NON-DRUG TREATMENT, NUMBER OF DRUGS AND SWITCHING FOR BIPOLAR DISORDER
COST CONSEQUENCE ASSOCIATED WITH DIFFERENT INITIAL MOOD STABILIZERS FOR NEWLY TREATED PATIENTS WITH BIPOLAR DISORDERS
EPILEPSY PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
WITHDRAWN
COST-EFFECTIVENESS OF RITALIN™ VERSUS ADDERALL™ FOR FIRST-LINE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN
SUICIDE ATTEMPTS BY THE ELDERLY
CORRELATIONS BETWEEN PSYCHOPATHOLOGY AND HEALTH RELATED QUALITY OF LIFE (HRQOL) MEASURES IN SCHIZOPHRENIA. RESULTS FROM THE SQUARE STUDY
DIFFERENTIAL IMPACT OF OLANZAPINE AND RISPERIDONE ON SEXUAL DYSFUNCTION AND ITS POTENTIAL IMPLICATIONS
REMISSION OF PSYCHOTIC SYMPTOMS AND LONG-TERM FUNCTIONAL OUTCOMES IN THE TREATMENT OF SCHIZOPHRENIA IN USUAL CARE
MAPPING UTILITY SCORES FROM THE EQ-5D AND SF-6D ONTO THE SCHIZOPHRENIA QUALITY OF LIFE SCALE
IMPROVEMENTS IN COGNITIVE DEFICITS ARE ASSOCIATED WITH IMPROVED FUNCTIONAL OUTCOMES
WEIGHT GAIN AND IMPROVEMENT IN PSYCHOPATHOLOGY DURING TREATMENT OF SCHIZOPHRENIA WITH ANTIPSYCHOTICS AND WITH PLACEBO
ASSESSMENT OF THE IMPACT OF QUETIAPINE TREATMENT ON PSYCHOPATHOLOGY, HEALTH RELATED QUALITY OF LIFE AND DISABILITY IN PATIENTS WITH SCHIZOPHRENIA IN GREECE.THE SQUARE STUDY
USING CLIENT AND STAFF STRUCTURED INPUT IN FORMATTING THE SCHIZOPHRENIA OUTCOMES ASSESSMENT PROJECT (SOAP) SURVEY
THE ROLE OF ANTIPARKINSONIAN AGENTS IN SELF-REPORTED COGNITIVE IMPAIRMENT AND AKATHISIA DURING THE LONG-TERM TREATMENT OF SCHIZOPHRENIA
WITHDRAWN
IMPROVEMENT IN QUALITY-OF-LIFE WITH RISPERIDONE AUGMENTATION IN TREATMENT-RESISTANT DEPRESSION
HOSPITALIZATION RATES DURING COMBINATION THERAPY WITH ATYPICAL ANTIPSYCHOTICS IN BIPOLAR DISORDER
WORK LOSS ASSOCIATED WITH BIPOLAR DISORDER
CHILD HEALTH ILLNESS PROFILE AS A QUALITY OF LIFE MEASURE OF CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
MENTAL HEALTH SERVICES AND DRUG UTILIZATION PATTERNS FOR STUDENTS WITH MENTAL ILLNESSES IN SCHOOL-BASED HEALTH CENTERS
THE EFFECT OF BEHAVIORAL CARVE-OUTS ON PHARMACEUTICAL USE AND EXPENDITURES
THE RELATIONSHIP BETWEEN MENTAL DISTRESS, HEALTH RISKS AND HEALTH CARE COSTS FROM THE MANAGED CARE HEALTH RISK ASSESSMENT DATABASE
ANTIPSYCHOTIC ADHERENCE AMONG CENTRAL TEXAS VETERANS
ANALYSIS OF LONGITUDINAL CLAIMS DATA TO EXAMINE FIRST AND SECOND-LINE USE OF PEMOLINE (CYLERT®)
TRENDS IN ANTIPSYCHOTIC PRESCRIBING TO CHILDREN AND ADOLESCENTS
HOSPITAL UTILIZATION FOLLOWING AN OPEN ACCESS POLICY FOR ATYPICAL ANTIPSYCHOTIC MEDICATIONS FOR PATIENTS WITH SCHIZOPHRENIA
TREND AND GEOGRAPHIC VARIATIONS IN THE LENGTH OF STAY FOR SCHIZOPHRENIA IN THE UNITED STATES
MISDIAGNOSIS OF BIPOLAR DISORDER AS UNIPOLAR DEPRESSION
SECOND SSRIS SWITCHING AND DISCONTINUATION AFTER FLUOXETINE INITIAL THERAPY
COMPARISON OF FIRST REFILL RATES AMONG BRANDED SSRI USERS
DEPRESSION DIAGNOSIS IN PRIMARY CARE VISITS NOT FOR MENTAL HEALTH REASONS
TRENDS IN PHARMACOLOGIC TREATMENT FOR PATIENTS WITH BIPOLAR
PATTERNS OF PHARMACOLOGIC TREATMENT FOR PATIENTS WITH BIPOLAR DISORDER
PHARMACOLOGIC TREATMENT PATTERNS FOR BIPOLAR DISORDER
WHEN BIPOLAR DISORDER IS BEING IDENTIFIED
MEDICATION PRESCRIBING PATTERNS FOR PATIENTS WITH BIPOLAR DEPRESSION
DEPRESSION IN THE GENERAL POPULATION AND AFTER STROKE
COMPARING PSYCHOMETRIC PROPERTIES OF SELF-VERSUS INTERVIEWER-RATED INSTRUMENTS USED IN CLINICAL TRIALS FOR PATIENTS WITH ANXIETY DISORDERS
DEVELOPMENT OF A PATIENT-REPORTED INSTRUMENT TO ASSESS THE FUNCTIONAL STATUS OF PATIENTS WITH BIPOLAR DISORDER
A COMPREHENSIVE RETROSPECTIVE STUDY OF ASSOCIATIONS BETWEEN DIABETES AND TREATMENT WITH RISPERIDONE, OLANZAPINE, QUETIAPINE, AND CONVENTIONAL ANTIPSYCHOTICS
ORDERING EFFECTS IN CROSSOVER STUDIES OF PHOTOTHERAPY
IDENTIFICATION OF DEPRESSION IN PATIENTS WITH LOW BACK PAIN
STATISTICALLY DETERMINING TREATMENT OF CHOICE FOR INDIVIDUAL PATIENTS WITH SCHIZOPHRENIA
HOW COGNITIVE FUNCTION AFFECTS ACTIVITIES OF DAILY LIVING IN PATIENTS WITH ALZHEIMER'S DISEASE
OXCARBAZEPINE REDUCES HOSPITALISATIONS FOR EPILEPTIC SEIZURES AND RELATED SYMPTOMS IN THE NETHERLANDS
PREDICTORS OF LOST PRODUCTIVITY AMONG EMPLOYEES WITH MIGRAINE HEADACHES IN A MEDICAL GROUP SETTING
IMPACT OF MIGRAINE AND NON-MIGRAINE HEADACHES ON EMPLOYEE PRODUCTIVITY IN A MEDICAL GROUP SETTING
COST-EFFECTIVENESS ANALYSIS OF RIZATRIPTAN AND SUMATRIPTAN VERSUS CAFERGOT IN THE ACUTE TREATMENT OF MIGRAINE
COMPARISON OF CLINICAL EFFICACY AND COST-EFFECTIVENESS BETWEEN ELETRIPTAN 40 MG AND SUMATRIPTAN IOOMG IN THE ACUTE TREATMENT OF MIGRAINE
A RETROSPECTIVE CLAIMS ANALYSIS OF THE DIRECT COSTS OF MIGRAINE AND ITS COMORBID CONDITIONS IN TAIWAN
TRIPTANS IN THE ACUTE TREATMENT OF MIGRAINE
COST EFFECTIVENESS ANALYSIS OF INTERFERON BETA-1A (AVONEX®) IN PRE-CLINICALLY DEFINITE MULTIPLE SCLEROSIS (CDMS)
COST-EFFECTIVENESS OF SCREENING FOR NEUTRALIZING ANTIBODIES TO INTERFERON BETAS IN THE TREATMENT OF MULTIPLE SCLEROSIS
HEALTH CARE COSTS FOR FLORIDA MEDICAID RECIPIENTS WITH MULTIPLE SCLEROSIS
COST UTILITY ANALYSIS OF INTERFERON BETA-1A (AVONEX®) IN PRE-CLINICALLY DEFINITE MULTIPLE SCLEROSIS (CDMS)
A COMPARATIVE COST ANALYSIS OF VASCULAR DEMENTIA VERSUS ALZHEIMER'S DISEASE IN TAIWAN
HEALTH CARE UTILIZATION AND EXPENDITURES AMONG MEDICAID PATIENTS WITH PARKINSON'S DISEASE
AN ECONOMIC ANALYSIS OF CALCIUM CHANNEL BLOCKERS FOR ACUTE TRAUMATIC BRAIN INJURY
FACTORS THAT DETERMINE EMPLOYABILITY IN EPILEPSY PATIENTS
VALIDATION OF THE CHILDHOOD HEALTH ASSESSMENT QUESTIONNAIRE (CHAQ) IN HUNTER SYNDROME
DEVELOPMENT AND PILOT TESTING OF THE HUNTER SYNDROME-FUNCTIONAL OUTCOMES FOR CLINICAL UNDERSTANDING SCALE (HS-FOCUS)
VALIDATION OF THE HUNTER SYNDROME-FUNCTIONAL OUTCOMES FOR CLINICAL UNDERSTANDING SCALE (HS-FOCUS)
UTILIZATION OF IMMUNOMODULATORY DRUG THERAPIES IN MULTIPLE SCLEROSIS (MS) IN NOVA SCOTIA, CANADA 1998–2003
INSOMNIA IN A NATIONAL AMBULATORY CARE SETTING 2001
THE SENSITIVITY OF COST-EFFECTIVENESS ESTIMATES IN MULTIPLE SCLEROSIS TO INTERNATIONAL DIFFERENCES IN NATURAL HISTORY
PROBABILISTIC SENSITIVITY ANALYSIS OF A COST-EFFECTIVENESS MODEL FORTRIPTANS (5-HT AGONISTS)
DEVELOPING A COMPUTER ALGORITHM TO IDENTIFY EPILEPSY CASES IN MANAGED CARE ORGANIZATIONS AND ESTIMATE PREVALENCE, INCIDENCE, AND MORTALITY
THE INFLUENCE OF BONE MINERAL DENSITY TESTING ON THE INITIATION OF AN OSTEOPOROSIS-RELATED PHARMACOTHERAPY
DIFFERENCES BETWEEN DOCTOR AND PATIENT RECALL OF EVENTS IN AND INVESTIGATIONS FOR OSTEOPOROSIS IN FIVE COUNTRIES
HEALTH CARE UTILIZATION AND EXPENDITURES
COST-EFFECTIVENESS OF LONG-TERM HORMONE REPLACEMENT THERAPY (ESTROGEN PLUS PROGESTIN) IN HEALTHY POSTMENOPAUSAL WOMEN FOR OSTEOPOROSIS PREVENTION
ECONOMIC EVALUATION OF SHORT-TERM NON-VERTEBRAL FRACTURE-RELATED COSTS AMONG OSTEOPOROSIS TREATMENTS
TERIPARATIDE VERSUS BISPHOSPHONATES IN HIGH RISK OSTEOPOROSIS PATIENTS
COST-EFFECTIVENESS OF TERIPARATIDE (FORTEO) IN THE PREVENTION OF OSTEOPOROTIC FRACTURES AMONG MEN AND POSTMENOPAUSAL WOMEN IN AUSTRALIA
ANTICIPATED PAIN PRIORTO SURGERY COMPARED TO ACTUAL PAIN IN PATIENTS UNDERGOING OUTPATIENT ARTHROSCOPIC KNEE PROCEDURES
THE DIRECT AND INDIRECT ECONOMIC IMPACT OF PAIN AND ITS COMPARISON WITH THREE OF THE TOP FIVE MOST COSTLY DISEASES
AN EVALUATION OF THE DIRECT COSTS OF ADVERSE Gl EVENTS ASSOCIATED WITH THE USE OF NSAIDS IN THE UNITED STATES
EXAMINATION OF TOTAL HEALTH CARE EXPENDITURES FOR PATIENTS ON LONG ACTING OPIOID MEDICATIONS FOR THE TREATMENT OF CHRONIC PAIN IN A MEDICAID POPULATION
AN OPIATE RENEWAL CLINIC
RELATIONSHIP BETWEEN PAIN AND PERCEIVED HEALTH STATUS IN OLDER PERSONS WITH POST-HERPETIC NEURALGIA
TRENDS IN MEDICAL USE AND ABUSE OF SUSTAINED-RELEASE OPIOID ANALGESICS
PATTERNS AND TRENDS IN OPIOID USE AMONG INDIVIDUALS WITH BACK PAIN IN THE UNITED STATES
PRESCRIPTION OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND MUSCLE RELAXANTS FOR BACK PAIN IN THE UNITED STATES
COMPARISON OF GENERALIZED LINEAR MODELS AND ORDINARY LEAST-SQUARES REGRESSION FOR COST ESTIMATION
MONTE-CARLO VALIDATION OF DELTA-K METHOD FOR SAMPLE-SIZE CALCULATION IN A COST-EFFECTIVENESS TRIAL
INCREMENTAL COST EFFECTIVENESS RATIOS AND CONFIDENCE INTERVALS—RELATIONSHIP OF CALCULATIONS WITH NNT VERSUS BOOTSTRAP METHODS
ISHIKAWA CAUSE AND EFFECT DIAGRAMS
TRACING THE DIFFUSION OF COST-UTILITY ANALYSIS AS AN INNOVATION
RESOURCE COSTING IN CLINICAL TRIALS
REGRESSION-BASED STATISTICAL MODEL AND PROPENSITY SCORE METHODS FOR THE EVALUATION OF COST-EFFECTIVENESS STUDIES
HAZARD ISOBARS
AGGREGATING COST DATA FROM MULTICENTER CLINICAL TRIALS
TESTING AND CORRECTING NON-RANDOM SELECTION BIAS
CHOOSING AMONG DIFFERENT TYPES OF BOOTSTRAPPING METHODS
MEDICATION COMPLIANCE AND CONCOMITANT THERAPY
ADHERENCE INDEX
STUDYING COMPLIANCE WITH MEDICATION IN CHRONIC ILLNESSES USING ADMINISTRATIVE DATA
RELIABILITY AND VALIDITY OF THE EQ-5D SELF-REPORT QUESTIONNAIRE IN TAIWAN POPULATION
INVESTIGATING THE CEILING EFFECT IN THE EUROQOL IN THE U.S GENERAL POPULATION
USING AN ARTIFICIAL NEURAL NETWORK TO PREDICT UTILITY SCORES FROM SF-36 DATA
REAL-LIFE PATIENT REPORTED OUTCOMES
TRAINING REGULATORY AGENCIES IN PRO EVALUATION
PRO INSTRUMENT DEVELOPMENT FOR RARE DISORDERS
A DESCRIPTIVE ANALYSIS TO INVESTIGATE THE DIFFERENCES BETWEEN TRADERS AND NON-TRADERS IN TIME TRADE OFF
PATIENT PREFERENCES FOR COMPUTER ASSISTED DATA COLLECTION AT THE CLINICAL INTERFACE
WHAT IS THE VALUE OF SOCIAL VALUES? THE USELESSNESS OF ASSESSING HEALTH-RELATED QUALITY OF LIFE THROUGH PREFERENCE MEASURES
EXPECTED VALUE OF SYMMETRY OF INFORMATION
ELICITING WILLINGNESS TO PAYWITHINTHE HEALTH SECTOR WITHOUT BIAS
UTILIZATION OF COMPLEMENTARY DATA SOURCES TO DEVELOP INDICATION ALLOCATIONS
THE APPLICATION OF TWO PRODUCTIVITY INSTRUMENTS AT A LARGE EMPLOYER
USING A WEB-PANEL TO AID DEFINITION OF A TARGET PATIENT POPULATION TO ASSIST RISK MANAGEMENT
MEASURING THE IMPACT OF AN ASTHMA DISEASE MANAGEMENT INTERVENTION ON PHARMACY AND IN-PATIENT SERVICE UTILIZATION IN A MANAGED CARE SETTING
THE PREVALENCE OF INAPPROPRIATE USE OF SHORT-ACTING ASTHMA MEDICATION
WEB-ENABLED ASTHMA APPLICATION FOR PERSONALIZED MEDICAL COMMUNICATION WITHIN A MULTI-GROUP PRACTICE SETTING
INHALED SALMETEROL UTILIZATION AND ASTHMA PATIENT OUTCOMES IN A GROUP-MODEL MANAGED CARE ORGANIZATION
LOCAL ADVERSE EVENT RATES AND COSTS ASSOCIATED WITH INHALED CORTICOSTEROIDS USE
RACIAL DIFFERENCES IN PHARMACOTHERAPYAND HEALTH CARE EXPENDITURES FOR THE TREATMENT OF ASTHMA IN A MEDICAID POPULATION
HEALTH CARE EXPENDITURES OF PATIENTS WITH COMORBID ALLERGIC RHINITIS AND ASTHMA
THE EFFECT OF HAVING A PRIMARY CARE PROVIDER ON ASTHMA HEALTH CARE EXPENDITURE AND HEALTH CARE UTILIZATION
ASTHMA-RELATED HEALTH CARE SERVICES UTILIZATION BY AFRICAN-AMERICANS IN A MEDICAID POPULATION
BUDGET IMPACT ANALYSIS
EFFECTIVENESS AND COST-BENEFIT OF LEUKOTRIENE MODIFIERS IN ADULTS WITH ASTHMA IN THE OHIO MEDICAID POPULATION
RESOURCE UTILIZATION (HOSPITAL AND PHYSICIAN COST/VISITS) BEFORE AND AFTER INTRODUCTION OF THE NEW TREATMENT GUIDELINES IN ASTHMA (1997) AND ODDS OF BEING ON APPROPRIATE ASTHMA THERAPY USING MULTIVARIATE LOGISTIC REGRESSION
COSTS FOR ASTHMA-RELATED MEDICAL SERVICES AND PRESCRIPTION MEDICATIONS IN A STATE MEDICAID PROGRAM
THE EFFECT OF MEDICAID COVERAGE DECISIONS ON NON-SEDATING ANTIHISTAMINE UTILIZATION AND SPENDING FOLLOWING OVER-THE-COUNTER AVAILABILITY OF LORATADINE
INVESTIGATION OF THE DETERMINANTS OF ADHERENCE IN ASTHMA USING Q METHODOLOGY
PREDICTORS OF SELF-REPORTED ADHERENCE IN PATIENTS WITH ASTHMA
THE ASSOCIATION BETWEEN ADHERENCE, ASTHMA CONTROL, GENERIC AND DISEASE SPECIFIC QUALITY OF LIFE INSTRUMENTS IN ASTHMA
THE ASSOCIATION BETWEEN MEASURES OF HEALTH STATE UTILITIES, QUALITY OF LIFE AND WILLINGNESS TO PAY IN ASTHMA
CONSUMER SATISFACTION WITH ASTHMA TREATMENT—WHAT MATTERS?
PREFERENCE SCORES FROM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) PATIENTS
THE ECONOMIC BURDEN OF ANEMIA IN AN INSURED POPULATION
WITHDRAWN
THE HEALTH-RELATED QUALITY OF LIFE EXPERIENCES OF YOUNG ADULTS WITH SICKLE CELL DISEASE
BLOOD DONATION IN THE 21ST CENTURY
GREATERAREA UNDER THE HEMOGLOBIN CHANGE CURVE DURING EPOETIN ALFA TREATMENT IS ASSOCIATED WITH IMPROVED PATIENT OUTCOMES
REPORT FROM THE FIRST MULTIDISCIPLINARY COST OF BLOOD CONSENSUS (COBCON) WORKING GROUP TO ESTABLISH STANDARD METHODOLOGY
ZIPRASIDONEVS OLANZAPINE
COMBINED LIPID GOAL ATTAINMENT IN THE MANAGED CARE SETTING
USING HEALTH-RISK APPRAISAL DATA FOR ASSESSING PREDICTORS OF HYPERTENSION TREATMENT
VARIABLE PATIENT COMPLIANCE WITH STATINS AND ASSOCIATED LIPID CONTROL AMONG CHINESE PATIENTS WITH HIGH RISK FOR CORONARY HEART DISEASE
PREDICTORS OF ADHERENCE WITH CONCOMITANT ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPY
ANALYZING RISK OF BLEEDING IN ADMINISTERING LOW MOLECULAR WEIGHT HEPARINS AND/OR ASPIRIN TO ORTHOPEDIC PATIENTS
EFFECTIVENESS OF LIPID-LOWERING THERAPY IN PRIMARY CARE IN FRANCE
WARFARIN ANTICOAGULATION AND OUTCOMES IN ATRIAL FIBRILLATION PATIENTS
LIPID MANAGEMENT AND FACTORS AFFECTING GOAL ATTAINMENT IN LATIN AMERICA
THE IMPACT OF ADEQUATE MONITORING OF LIPID LEVELS IN PATIENTS HAVING ELECTIVE PERCUTANEOUS CORONARY INTERVENTIONS IN A LOCAL PUBLIC HOSPITAL IN HONG KONG
EVALUATING CLINICAL OUTCOMES FOR SUBJECTS THAT ARE NEWLY INITIATED ON HMG-COA REDUCTASE INHIBITORS IN A NATURALISTIC ENVIRONMENT USING LONGITUDINAL DESIGN
UTILIZATION PATTERNS OF HYPERTENSION THERAPIES AMONG PATIENTS INITIATING ANGIOTENSION II RECEPTOR ANTAGONIST THERAPY
RECENT EVIDENCE SURROUNDING THE EFFICACY OF PROTECTED CAROTID ANGIOPLASTY WITH STENTS
A COMPARISON OF THE RISK OF ADVERSE THROMBOEMBOLIC AND BLEEDING EVENTS BETWEEN SUBJECTS TREATED AND NOT TREATED WITH WARFARIN
ECONOMIC EVALUATION OF GLYCOPROTEIN MB/MIA ANTAGONISTS IN DIABETIC PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS WITH STENTING
DIFFERENCES IN RESOURCE UTILIZATION IN POST-MI PATIENTS WITH AND WITHOUT HEART FAILURE
A COST-UTILITY ANALYSIS OF LOSARTAN VERSUS ATENOLOL IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION
COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PRAVASTATIN, AND SIMVASTATIN
GENDER AND STATIN THERAPY COST AND EFFICACY
RATES OF HYPERTENSION-RELATED MEDICAL AND PRESCRIPTION UTILIZATION AND COSTS IN A STATE MEDICAID POPULATION
PREVALENCE AND COST IMPLICATIONS OF POTENTIAL INTERACTIONS WITH STATIN MEDICATIONS IN A MANAGED CARE POPULATION
COST AND COMORBIDITIES ASSOCIATED WITH ATRIAL FIBRILLATION IN DIFFERENT AGE GROUPS
HEALTH CARE AND DRUG UTILIZATION PATTERNS IN PATIENTS RECEIVING LONG TERM THIENOPYRIDINE THERAPY
7309 HEALTH CARE RESOURCE UTILIZATION BY PATIENTS WITH ESSENTIAL HYPERTENSION
TOBACCO COST-EFFECTIVENESS ANALYSES AND THE PAYER
MEDICARE EXPENDITURES IN RELATION TO FUNCTIONAL HEALTH STATUS POST-STROKE FORA NATIONALLY-REPRESENTATIVE SAMPLE OF MEDICARE BENEFICIARIES FROM 1996 TO 2000
HOSPITALIZATION COSTS AND LENGTH OF STAY IN POST-MI PATIENTS WITH HEART FAILURE
AN ARB COST-EFFECTIVENESS MODEL IN TREATING MILD-TO-MODERATE HYPHERTENSION
COST EFFECTIVENESS ANALYSIS OF THERAPY MODIFICATION AFTER FAILING STATIN TREATMENT
COST-EFFECTIVENESS OF STATINS IN CARDIOVASCULAR RISK MANAGEMENT
ECONOMIC ANALYSIS OF AMIODARONE, ATRIAL SEPTAL PACING, AMIODARONE PLUS ATRIAL SEPTAL PACING VERSUS STANDARD OF CARE TO PREVENT ATRIAL FIBRILLATION AFTER OPEN-HEART SURGERY
USE OF ANTILIPEMIC DRUGS IN NATIONAL HEALTH CARE GROUP (NHG), SINGAPORE
COST ANALYSIS OF A PRIOR AUTHORIZATION PROGRAM FOR ANTI-OBESITY THERAPY IN A MEDICAID POPULATION
QUALITY OF LIFE FROM THE MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE FOLLOWING AORTIC VALVE REPLACEMENT SURGERY
VALIDATION OF THE EQ-5D QUESTIONNAIRE IN PATIENTS WITH A HISTORY OF ACUTE CORONARY SYNDROME
THE IMPACT OF ACEI RELATED COUGH
HEALTH-RELATED QUALITY OF THE LIFE OF PATIENTS MAKING AN ATTEMPT AT SMOKING CESSATION
HEALTH-RELATED QUALITY OF LIFE IN AN ACUTE CORONARY SYNDROME POPULATION IS AFFECTED BY DEPRESSION TREATMENT ADEQUACY
HEALTH STATUS IN HIGH-RISK PATIENTS UNDERGOING NONCARDIAC VASCULAR SURGERY IN THE UNITED STATES
ASSESSMENT OF THE QUALITY OF DRUG TREATMENT IN CORONARY ARTERY DISEASE USING QUALITY INDICATORS
MEDICATION POSSESSION RATIOS FOR PATIENTS WITH CALCIUM CHANNEL BLOCKERS AND/OR STATINS
PERSISTENCE AND ADHERENCE TO STATIN THERAPY IN A MANAGED CARE SETTING
EVALUATION OF THE ASSOCIATION BETWEEN HEALTH-RELATED UTILITY AND OBESITY IN HOSPITAL TREATED SUBJECTS
BMI, SELF-REPORTED COMORBIDITIES, AGE, AND GENDER DO NOT EXPLAIN COUNTRY-SPECIFIC DIFFERENCES IN OBESITY-RELATED QUALITY OF LIFE
MECHANICAL AND ALLERGIC ADVERSE EVENTS RELATED TO CENTRAL VASCULAR CATHETERS
EXPLORATION OF HIGHLY ELEVATED CREATININE KINASE RESULTS AND ASSOCIATED CHOLESTEROL THERAPY IN A LARGE COMMERCIAL HEALTH PLAN
THE NATIONAL ANTICOAGULATION BENCHMARK AND OUTCOMES REPORT (NABOR™)
OBESITY AMONG HIGH SCHOOL STUDENT AND CONTRIBUTING FACTORS
DOES THE RATE OF MEDICARE MANAGED-CARE PENETRATION AFFECT AVAILABILITY OF RESOURCES FOR HEART FAILURE TREATMENT?
GASTRIC BYPASS SURGERY—AN OVERVIEW
RETROSPECTIVE EVALUATION OF UTILIZATION PATTERNS OF BETA-BLOCKERTHERAPY IN CONGESTIVE HEART FAILURE PATIENTS IN A MANAGED CARE ENVIRONMENT
IMPACT OF MARKET FORCES ON STATIN PERSISTENCE PATTERS IN A CALIFORNIA MEDICAID POPULATION
IMPACT OF THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT) ON PHYSICIAN PRESCRIBING PATTERNS AND PATIENT UTILIZATION OF ANTIHYPERTENSIVE MEDICATIONS LkLX,
IMPACT OF THE NATIONAL SERVICE FRAMEWORK (NSF) FOR CORONARY ARTERY DISEASE (CAD) ON PHYSICIAN COMPLIANCE OF PRESCRIBING ASPIRIN AND STATINS FOR SECONDARY PREVENTION IN THE UNITED KINGDOM (UK)
DELAY IN DIAGNOSIS AS A FACTOR IN INITIATION OF TREATMENT FOR HYPERCHOLESTEROLAEMIA
DELAY IN DIAGNOSIS AS A FACTOR IN INITIATION OF TREATMENT FOR HYPERTENSION
ASSOCIATION BETWEEN INSURANCE COVERAGE AND OUTCOMES FOR INDIVIDUALS HOSPITALIZED FOR NONHEMORRHAGIC STROKE
USE OF GPIIB/IIIA INHIBITORS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WITH DRUG-ELUTING STENTS
CLINICAL PHARMACIST INVOLVMENT IN COMMUNITY ANTICOAGULATION CONTROL
DISORDERS OF LIPOID METABOLISM
LOWER INCIDENCE OF MICROVASCULAR EVENTS ASSOCIATED WITH PIOGLITAZONE MONOTHERAPY THAN INSULIN MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES
COMPARISON OF PIOGLITAZONE WITH OTHER ANTIDIABETIC DRUGS FOR ASSOCIATED INCIDENCE OF LIVER FAILURE
EVALUATION OF PHARMACIST INTERVENTIONS IN DIABETIC PATIENTS FROM RURAL COMMUNITY HEALTH CENTERS
PARTICIPATION IN HOME-BASED AIC TESTING IN CAREPATTERNS® PROGRAM FOR DIABETES
SELF-MONITORING OF BLOOD GLUCOSE AMONG VETERANS WITH DIABETES MANAGED ON ORAL THERAPY
GENDER DISPARITY IN THE MANAGEMENT OF DYSLIPIDEMIA AMONG TYPE 2 DIABETES PATIENTS IN A MANAGED-CARE SETTING
ALTERNATIVE ANTIPSYCHOTIC TREATMENT AND RISK OF DIABETES
THE ROLE OF INTRAOPERATIVE PARATHYROID HORMONE MONITORING FOR PARATHYROID HYPERPLASIA
POTENTIAL MEDICAL COST REDUCTION DUE TO DECREASES IN AIC RESULTING FROM PHARMACIST DIABETES EDUCATON AND MEDICATION RECOMMENDATIONS IN A COMMUNITY SETTING
UTILIZATION PATTERNS OF DRUGS AND HEALTH CARE SERVICES AMONG RECIPIENTS WITH DIABETES IN A MEDICAID POPULATION
DIFFERENCES IN HYPOGLYCEMIA EVENT RATES AND ASSOCIATED COST-CONSEQUENCE IN PATIENTS INITIATED ON LONG-ACTING AND INTERMEDIATE-ACTING INSULIN PRODUCTS
ESTIMATING THE REDUCTION IN LONG TERM COMPLICATION AND COSTS OF COMPLICATIONS IN TYPE I DIABETES BY REDUCED AIC LEVELS DUE TO MORE FREQUENT BLOOD GLUCOSE MONITORING
PHARMACY AND MEDICAL RESOURCE UTILIZATION AMONG INITIAL METFORMIN AND THIAZOLIDINEDIONE PATIENTS
PROPENSITY SCORE METHODS FOR REDUCING BIAS IN THE COMPARISON OF COSTS AND UTILIZATION BETWEEN INSULIN LISPRO AND REGULAR INSULIN
TOTAL CHOLESTEROL, HDL CHOLESTEROL AND HBAIC AFFECT QUALITY-ADJUSTED LIFE YEARS AND HOSPITAL COSTS FOR PATIENTS WITH TYPE 2 DIABETES IN THE UNITED KINGDOM—THE CARDIFF DIABETES COST UTILITY MODEL
THE ECONOMIC AND HEALTH OUTCOMES OF USING DIFFERENT INSULIN DELIVERY DEVICES IN A MANAGED CARE ENVIRONMENT
RETIREE TYPE 2 DIABETES HEALTH CARE COSTS FOR A SELF-INSURED TELECOMMUNICATIONS COMPANY
INCREASED HEALTH EXPENDITURES AMONG DIABETES PATIENTS ON INSULIN WITH HYPOGLYCEMIA
THE ECONOMIC BURDEN OF TYPE 2 DIABETES MANAGEMENT BY ETHNIC GROUP IN THE TEXAS MEDICAID POPULATION
COST-EFFECTIVENESS OF DULOXETINE VERSUS ROUTINE TREATMENT FOR PAINFUL DIABETIC NEUROPATHY IN A RANDOMIZED TRIAL FROM A SOCIETAL PROSPECTIVE
THE IMPACT OF COMMON DIABETIC COMPLICATIONS ON QUALITY OF LIFE
THE VALUE TO HIGH-RISK PATIENTS OF PREVENTING A CASE OF DIABETES
IS PSYCHOLOGICAL GENERAL WELL-BEING AN IMPORTANT PATIENT-REPORTED OUTCOME FOR THE EVALUATION OF DIABETES DRUG THERAPY?
COMPARE USABILITY OF TWO TYPES OF DISPOSABLE PEN (FLEXPEN VERSUS HUMALOG PEN) CONTAINING RAPID-ACTING INSULIN ANALOGUES
PAIN SEVERITY AFFECTS PERCEIVED HEALTH STATUS IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHY
PREFERENCE, EFFICACY, SAFETY AND ACTUAL USE OF BLOOD GLUCOSE (BG) MONITORING WITH INDUO® VS SYRINGE AND SEPARATE METER IN SUBJECTS WITH TYPE I DIABETES
HOSPITALIZATIONS WITHIN THE VA AMONG VETERANS WITH DIABETES
GLYCEMIC CONTROL AS A CLINICAL OUTCOME VARIABLE
VALIDATION OF THE DIABETES RESOURCE CONSUMPTION INDEX (DRCI)
DEVELOPMENT OF A DIABETES RESOURCE CONSUMPTION INDEX (DRCI) USING VETERANS HEALTH ADMINISTRATION DATA
GASTROINTESTINAL ADVERSE EVENTS FROM NON STEROIDAL ANTI-INFLAMMATORY DRUGS
A SYSTEMATIC REVIEW OF THE EFFECTIVENESS OF TOTAL AND PARTIAL LAPAROSCOPIC FUNDOPLICATION FOR THE TREATMENT OF GORD
COST-UTILITY ANALYSIS COMPARING ESOMEPRAZOLE WITH THE ORO-DISPERSIBLE FORMULATION OF LANSOPRAZOLE IN THE INITIAL TREATMENT OF REFLUX OESOPHAGITIS
IMPATIENT COSTS OF LIVER CIRRHOSIS IN THE UNITED STATES
COST-EFFECTIVENESS OF TREATING ADULTS WITH CHRONIC HEPATITIS C (CHC) AND PERSISTENTLY NORMAL ALANINE AMINOTRANSFERASE (PNALT) WITH PEGINTERFERON ALFA-2A (40 KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS)
ECONOMIC BURDEN OF GERD AND PUD IN AN EMPLOYED POPULATION
FECAL LACTOFERRIN ASSAY FOR THE INITIAL DIAGNOSTIC APPROACH TO SYMPTOMATIC PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS
A PHARMACOECONOMIC ASSESSMENT OF THE BENEFITS AND COSTS OF MANAGING IMMUNOSUPPRESSION IN POST-LIVER TRANSPLANT PATIENTS
RESPONSIVENESS TO CHANGE AND ENGLISH LANGUAGE VALIDATION OF THE WPAI-GERD QUESTIONNAIRE-RESULTS FROM A CANADIAN STUDY
WORK LOSS AND ACTIVITY IMPAIRMENT DUE TO INFLAMMATORY BOWEL DISEASE
RETROSPECTIVE ANALYSIS OF A PRIOR AUTHORIZATION PROGRAM USING COX-2 INHIBITORS IN A MANAGED CARE POPULATION
EVALUATING THE GERD SYMPTOM AND MEDICATION QUESTIONNAIRE (GERD-SMQ) IN A CLINICAL TRIAL
OUTCOMES OF AN INTERACTIVE VOICE RESPONSE (IVR) REMINDER SYSTEM TO PROMOTE MANAGED CARE ORGANIZATION (MCO) MEMBERS' ATTAINMENT OF INFLUENZA IMMUNIZATION
RETREATMENT RATES OF ACUTE OTITIS MEDIA IN PATIENTS WITH TYMPANOSTOMY TUBES WITHIN THE LOUISIANA MEDICAID PROGRAM
OUTCOMES FOLLOWING THE USE OF AZITHROMYCIN OR CLARITHROMYCIN FOR RESPIRATORY TRACT INFECTIONS IN A MEDICAID POPULATION
EXAMINATION OF HEPATITIS C IN THE LOUISIANA MEDICAID POPULATION
A META-ANALYSIS OF THREE-DAY AZITHROMYCIN THERAPY VERSUS LONGER COURSES OF COMPARATOR ANTIBIOTICS IN ACUTE SINUSITIS
TAMPON-RELATED TOXIC SHOCK SYNDROME (TSS) CONTINUES TO PEAK AMONG ADOLESCENT GIRLS
CHANGES IN HIV ANTIVIRAL PHENOTYPIC DRUG RESISTANCE DURING THE HAART ERA
AN EVIDENCE BASED PROPOSAL TO MODIFY PRESCRIBING PATTERNS
VARIABILITY IN THE USE OF HIV PHENOTYPIC TESTING BY SPECIALTY OF PRACTITIONER
OFF-LABEL USE OF PIPERACILLIN/TAZOBACTAM (ZOSYN®) IN A PEDIATRIC UNIT
TESTING AND TREATMENT OF HEPATITIS C IN THE LOUISIANA MEDICAID POPULATION
COST-EFFECTIVENESS OF INTRAVENOUS IMMUNOGLOBULIN MANUFACTURED FROM CHROMOTOGRAPHY-CAPRYLATE VS. SOLVENT-DETERGENT METHODS IN PERSONS WITH PRIMARY IMMUNODEFICIENCY DISEASE
AN ECONOMIC AND CLINICAL ASSESSMENT OF FIRST-LINE MONOTHERAPY IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA WITHIN MANAGED CARE
ECONOMIC COST STRUCTURE OF SEVERE SEPSIS MANAGEMENT
THE COST OF TREATMENT FAILURE IN ACUTE BACTERIAL MAXILLARY SINUSITIS
COST-EFFECTIVENESS OF FOUR ANTIMICROBIAL REGIMENS IN PATIENTS ADMITTED TO THE MEDICAL FLOOR WITH CLASS IV OR V COMMUNITY-ACQUIRED PNEUMONIA
COST-EFFECTIVENESS MODELING OF TREATMENT APPROACHES TO HEPATITIS C
DIRECT TREATMENT COSTS OF TINEA CAPITIS AMONG THE UNITED STATES PRIVATELY INSURED POPULATION
THE COST-EFFECTIVENESS ANALYSIS OF COMBINATION OF PEGINTERFERON ALFA-2A AND RIBAVIRIN VERSUS COMBINATION OF PEGINTERFERON ALFA-2B AND RIBAVIRIN IN CHRONIC HEPATITIS C IN POLAND
BURDEN OF ILLNESS OF BACTERIAL CELLULITIS AND ERYSIPELAS OF THE LEG IN THE NETHERLANDS
COMPARISON OF 30-DAY DIRECT MEDICAL COSTS OF AZITHROMYCIN AND LEVOFLOXACIN FOR PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA
HOSPITAL UTILIZATION TRENDS OF HIV DISEASE IN THE UNITED STATES, 1993 TO 2001
CLINICAL AND ECONOMIC IMPACT OF HERD IMMUNITY ASSOCIATED WITH HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN CANADA
ANTIBIOTIC PRESCRIBING RATES IN AMBULATORY CARE SETTINGS FOR PATIENTS DIAGNOSED WITH INFLUENZA, 1997–2001
COSTS AND OUTCOMES OF EXTENDED-RELEASE CLARITHROMYCIN FOR LOWER RESPIRATORY TRACT INFECTIONS
MENINGOCOCCAL VACCINE IN PORTUGAL—A COST-EFFECTIVENESS ANALYSIS
THE IMPACT OF PHYSICIAN PROFILING ON ANTIBIOTIC COST AND UTILIZATION
MEDICOECONOMIC EVALUATION OF OUTPATIENT MANAGEMENT OF INFANTILE BRONCHIOLITIS IN FRANCE
THE ECONOMIC EVALUATION OF INFLUENZA VACCINATION IN THE ELDERLY POPULATION
OBSERVATIONAL STUDY ON THE “REAL LIFE” PRACTICE AND COST OF ANTIBIOTIC (AB) MEDICATION IN PNEUMOCOCCAL PNEUMONIA PATIENTS
SUBSTITUTION TO LOPINAVIR/RITONAVIR (LPV/R) IS ASSOCIATED WITH IMPROVED PATIENT-REPORTED FATIGUE IN HIV+ PATIENTS EXPERIENCING SIDE EFFECTS RELATED TO THEIR PROTEASE INHIBITOR (PI)/NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI)
ACUTE SINUSITIS IN MANAGED CARE
UTILIZATION PATTERNS OF MEDICAL SERVICES AND PRESCRIPTION DRUGS FOR THE TREATMENT OF TINEA CAPITIS
THE USE OF ANTIBIOTICS TO TREAT ACUTE UPPER RESPIRATORY TRACT INFECTIONS IN A STATE MEDICAID POPULATION
A SELF-ADMINISTERED SCREENER FOR MALE ERECTILE DISFUNCTION
ANTIDEPRESSANT-INDUCED SEXUAL DYSFUNCTION (ADSD) IN EUROPE
TOTAL HEALTH CARE COSTS FOR BENIGN PROSTATIC HYPERPLASIA PATIENTS ON ALPHA I-BLOCKER TREATMENT IN A MANAGED CARE SETTING
WITHDRAWN
REACHING TARGET HEMATOCRITS WITH EPOETIN
A COST COMPARISON ANALYSIS OF TWO CLINICALLY UROSELECTIVE ALPHA BLOCKERS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
DITROPAN XL PROVIDES SUPERIOR OUTCOMES AND LOWER COSTS COMPARED TO DETROL LA
OVERACTIVE BLADDER
THE COST-EFFECTIVENESS OF SIROLIMUS WITH CYCLOSPORIN WITHDRAWAL VERSUS LOW DOSE SIROLIMUS AND CONTINUED CYCLOSPORIN WHEN INITIATED WITHIN FOUR MONTHS OF RENAL TRANSPLANTATION
THE RELATIONSHIP BETWEEN COST OF CARE AND COMORBIDITY IN CHRONIC KIDNEY DISEASE
A COST EVALUATION OF CYCLOPHOSPHAMIDE PLUS PREDNISONE VERSUS AZATHIOPRINE PLUS PREDNISONE FOR TREATMENT OF LUPUS NEPHRITIS
COST-EFFECTIVENESS ANALYSIS OF THE TREATMENT OF URINARY TRACT INFECTIONS IN A COLLEGE-AGE POPULATION
ECONOMIC IMPACT OF EPOETIN ALFA (EPO) TREATMENT AMONG NON-DIALYSIS CHRONIC KIDNEY DISEASE (NDCKD) PATIENTS WITH ANEMIA
USING CONJOINT ANALYSIS TO EXAMINE PATIENT QUALITY OF LIFE AND PRESCRIPTION INSURANCE COVERAGE PREFERENCES IN THE MANAGEMENT OF OVERACTIVE BLADDER
PATIENT PERSISTENCY WITH MEDICATIONS FOR OVERACTIVE BLADDER
PROSPECTIVE URINARY INCONTINENCE RESEARCH (PURE)
VALIDATION OF AUTOMATED DATABASE ALGORITHMS TO IDENTIFY HOSPITAL-ACQUIRED ACUTE RENAL FAILURE
A COST MINIMIZATION ANALYSIS OF FOMEPIZOLE VERSUS ETHANOL WITH OR WITHOUT HEMODIALYSIS IN THE ACUTE MANAGEMENT OF METHANOL OR ETHYLENE-GLYCOL POISONING
HOSPITALIZATIONS FOR INJURIES FROM FIREWORKS
HANDGUN INJURIES TO CHILDREN AND TEENS RESULTING IN HOSPITALIZATION
BURDEN OF ILLNESS FOR EMPLOYEES WITH PAINFUL CONDITIONS
EVALUATING THE COSTS OF DISEASES IMPUTABLE TO STRESS AT WORK
THE SOCIOECONOMIC COST OF DISEASES DUE TO SMOKING IN KOREA
THE SOCIOECONOMIC COST OF DISEASES IN KOREA
PEER PRESSURE IN HEALTH CARE
RELATIONSHIP BETWEEN PATIENT-REPORTED READINESS, SELF-MANAGEMENT BEHAVIOR, AND HEALTH STATUS IN MANAGED-CARE PATIENTS WITH CHRONIC CONDITIONS
EQUITY IN THE NATIONAL HEALTH INSURANCE DURING ECONOMIC RECESSION
ESTIMATING THE ABILITY-TO-PAY FOR HEALTH CARE EXPENDITURES RISING FASTER THAN GDP
FACTORS AFFECTING CONSUMER VIEWS REGARDING GENERIC DRUG SUBSTITUTION PRACTICES
WHO BENEFITS FROM OVER-THE-COUNTER (OTC) MEDICATION COVERAGE IN A STATE MEDICAID PROGRAM?
ADDITION OF PHARMACY COST DATA IMPROVES PERFORMANCE OF THE ADJUSTED CLINICAL GROUPS PREDICTIVE MODEL FOR TOTAL HEALTH CARE COSTS OVERALL AND WITHIN DISEASE SPECIFIC GROUPS
INCLUDING CARER UTILITY IN ECONOMIC EVALUATIONS
FAMILIES, FRIENDS AND COST,EFFECTIVENESS ANALYSIS
RECENT TRENDS IN IMPATIENT DRUG COSTS
PREVALENCE OF DRUG,RELATED PROBLEMS AMONGST HOSPITALISED PATIENTS ON POLYPHARMACY IN SINGAPORE
COMPARING THE COSTS OF MAIL ORDER AND RETAIL PHARMACY
FACTORS THAT INFLUENCE PRESCRIBING DECISIONS
E,COMMERCE ON PHARMACEUTICALS
TRENDS IN APPROVALS BY THE PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE
PHARMACEUTICAL PRESCRIPTION
QUALITY OF DECISION-MAKING BY THE PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) AND THE IMPACT ON OUTCOMES
ASSESSMENT OF THE IMPACT OF “ACADEMIC DETAILING” IN PROMOTING COST-EFFECTIVE GENERIC DRUG PRESCRIPTION AMONG AMBULATORY CARE PHYSICIANS IN WEST VIRGINIA
CCOHTA GUIDELINES FOR THE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES
INFLATION
PATIENT SATISFACTION—PATIENT EDUCATION INTERFACE
CONSUMER SATISFACTION WITH HEALTH PLANS AND DRUG BENEFIT MANAGEMENT STRATEGIES
PATIENT SATISFACTION WITH HEALTH CARE SERVICES
POTENTIALLY INAPPROPRIATE PRESCRIBING FOR OLDER VETERANS
HEALTH-RELATED QUALITY OF LIFE AND HEALTH PREFERENCE AS PREDICTORS OF MORTALITY AMONG OLDER PEOPLE AT VETERAN HOME
FACTORS ASSOCIATED WITH TTO UTILITY CHANGES AMONG OLDER PEOPLE AT VETERAN HOME
EXPLICIT INDICATORS TO MEASURE PREVENTABLE DRUG-RELATED MORBIDITY IN AN ELDERLY POPULATION
JUDGMENT RULES IN OLDER ADULTS' EVALUATIONS OF DRUG BENEFIT PLANS
PRESCRIPTION DRUG UTILIZATION PATTERNS AND CHARACTERISTICS FOR A MEDICARE POPULATION IN MANAGED CARE
CONTENT ANALYSIS OF PRINT DIRECT TO CONSUMER DRUG ADVERTISEMENTS TO DETERMINE NUMBER AND SPECIFICITY OF RISK STATEMENTS
AN ASSESSMENT OF THE EFFECT OF DEMOGRAPHICAL AND SOCIOLOGICAL FACTORS ON INDIVIDUAL RESPONSE TO DIRECT-TO-CONSUMER ADVERTISING OF PRESCRIPTION DRUGS
STOCK MARKET VALUATION AND FIRM-LEVEL DETERMINANTS OF INNOVATIVE ACTIVITY IN THE PHARMACEUTICAL INDUSTRY
POST-LAUNCH STUDIES—WHAT IS DESIRABLE, WHAT IS FEASIBLE?
PARALLEL TRADE OF PHARMACEUTICALS AS A COST-CONTAINMENT MEASURE-ANALYSIS OF THE ISRAELI EXPERIENCE
METHODS FOR “GO/NO-GO” MODELING OF COMPOUNDS IN THE DEVELOPMENT PIPELINE
THE IMPACT OF PRICE CONTROLS ON PHARMACEUTICAL R&D INVESTMENT